Transcode Therapeutics, Inc. (RNAZ): Nasdaq/NYSE listing notice — TransCode Therapeutics receives Nasdaq bid price deficiency notice; faces dual listing compliance issues

Transcode Therapeutics, Inc.

Common stock failed minimum $1.00 closing bid for 30 consecutive days through Nov 6, 2023.
Company has 180 calendar days, until May 6, 2024, to regain bid price compliance.
Also under stockholders' equity deficiency; Nasdaq panel granted exception until Jan 22, 2024 to demonstrate compliance.
Company may consider a reverse stock split to regain compliance with bid price rule.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Transcode Therapeutics, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5815(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: stockholders equity
Rules: 5815(a)(2)

Exact text from the filing

October 26, 2023, the Company received written notice from Nasdaq (the “October Notification Letter”) that the Panel had granted the Company an exception from compliance with the Stockholders Equity Requirement and extension of continued listing until January 22, 2024, subject to the following: 1. On or before November 14, 2023, the Company shall provide a detailed update to the Panel regarding its meeting the Stockholders’ Equity Requirement; and 2. On or before January 22, 2024, the Company shall provide an update to the Panel on how it demonstrates long-term compliance with the Stockholders

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Transcode Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-116285

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.